NOX 1.45% 6.8¢ noxopharm limited

Impact of COVID-19 on clinical trials and clinical research: A...

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    Impact of COVID-19 on clinical trials and clinical research: A systematic review (nih.gov)

    Conclusion

    The COVID-19 pandemic has resulted in a series of public health policies that have crippled the healthcare systems of many countries. This situation hugely impacted the study participants, care providers, researchers, trial sponsors, and research organizations concerning clinical trials. This pandemic has a substantial impact on the trial sites as they experience difficulty in the continuation of trial activities which eventually hampers the progress of the trial and delays study timelines. Most sites are struggling due to delayed subject enrollment, shortfalls in monitoring, and risks of compromised data integrity, and this situation has negatively impacted the initiation of future trials as well ...


    Meanwhile, Noxopharm and its collaborators continue with their voyage of discovery, as witnessed by the publication yesterday of a 92-page patent application that included 18 pages of astounding pre-clinical data.

    Interestingly, the Inflammation application mentions the potential for nasal, oral, intravenous or rectal delivery; and an as-yet-unpublished application is entitled "Improved Isoflavone Formulation"; so it looks like we have more exciting news on the way.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
6.8¢
Change
-0.001(1.45%)
Mkt cap ! $19.87M
Open High Low Value Volume
6.8¢ 6.8¢ 6.6¢ $10.20K 152.8K

Buyers (Bids)

No. Vol. Price($)
2 51263 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
6.9¢ 59000 1
View Market Depth
Last trade - 12.52pm 27/06/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.